Open Access

Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: A case report

  • Authors:
    • Kunihiko Kobayashi
    • Kyoichi Kaira
    • Hidetoshi Iemura
    • Shun Shinomiya
    • Kosuke Hashimoto
    • Yu Miura
    • Ayako  Shiono
    • Fuyumi Nishihara
    • Hiroshi Kagamu
  • View Affiliations

  • Published online on: September 7, 2021     https://doi.org/10.3892/mco.2021.2390
  • Article Number: 227
  • Copyright: © Kobayashi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study selected two patients with lung cancer and epidermal growth factor receptor (EGFR) mutations who were treated with a programmed cell death protein 1 (PD‑1) antibody and an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis. In the first case, a 67‑year‑old female was diagnosed with lung adenocarcinoma with an EGFR mutation (exon 19 deletion) and Stage IVB disease. Initial treatment with an EGFR mutation‑targeted tyrosine kinase inhibitor (TKI), erlotinib, demonstrated a partial response. After disease progression this was followed by carboplatin and pemetrexed with bevacizumab, and re‑challenged by erlotinib plus bevacizumab; however, the tumor eventually progressed. Subsequently, the patient was treated with immunomodulatory arabinomannan for 3 months. Immediately after, she was treated with nivolumab and showed a partial response. In the second case, a 57‑year‑old male with a history of smoking was diagnosed with stage IVB pulmonary adenocarcinoma with an EGFR mutation (exon 19 deletion). He was treated with afatinib, followed by osimertinib when a T790M mutation was identified later. After disease progressed with TKIs, cisplatin plus pemetrexed and re‑challenge with erlotinib plus bevacizumab were administered subsequently. Nivolumab was administered for recurrent disease. Although he experienced tumor remission, regrowth of the tumors was observed. Under continuing nivolumab, he was treated by palliative irradiation treatments to the right pelvic bone metastasis and left adrenal metastasis with immunomodulatory arabinomannan. A chest computed tomography scan showed a reduction in the sizes of the primary site and pulmonary metastases, with a decreasing trend of carcinoma embryonic antigen. Overall, these cases may indicate that the immune adjuvant actions of immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis improves the effect of PD‑1 antibody treatments.
View Figures
View References

Related Articles

Journal Cover

November-2021
Volume 15 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kobayashi K, Kaira K, Iemura H, Shinomiya S, Hashimoto K, Miura Y, Shiono A, Nishihara F and Kagamu H: Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from <em>Mycobacterium tuberculosis</em>: A case report. Mol Clin Oncol 15: 227, 2021
APA
Kobayashi, K., Kaira, K., Iemura, H., Shinomiya, S., Hashimoto, K., Miura, Y. ... Kagamu, H. (2021). Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from <em>Mycobacterium tuberculosis</em>: A case report. Molecular and Clinical Oncology, 15, 227. https://doi.org/10.3892/mco.2021.2390
MLA
Kobayashi, K., Kaira, K., Iemura, H., Shinomiya, S., Hashimoto, K., Miura, Y., Shiono, A., Nishihara, F., Kagamu, H."Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from <em>Mycobacterium tuberculosis</em>: A case report". Molecular and Clinical Oncology 15.5 (2021): 227.
Chicago
Kobayashi, K., Kaira, K., Iemura, H., Shinomiya, S., Hashimoto, K., Miura, Y., Shiono, A., Nishihara, F., Kagamu, H."Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from <em>Mycobacterium tuberculosis</em>: A case report". Molecular and Clinical Oncology 15, no. 5 (2021): 227. https://doi.org/10.3892/mco.2021.2390